Thanks for your observations and question marks, Dew.
Considering the financial commitments assumed by GTCB in the agreements with LFB, I am wondering how their financial strategy looks like over the years to come. They seem confident to play the equal partner role vis-a-vis LFB, but IMO can only do that if they have access to the deep pockets of a big pharmaceutical company, in other words they must be sure to find a big partner or to be taken over.
In any case, the broader the (transgenic) pipeline, the more serious they will be taken by the pharmaceutical community.
